ARWR Overview
Upcoming Projects (ARWR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ARWR)
-
Discussing Arrowhead’s Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Ticker: ARWR
Executed On: Jul 16, 2020 at 02:30 PM EDT -
Investigating the siRNA approaches to Alpha-1 Antitrypsin Deficiency Liver Disease from Arrowhead and Alnylam
Tickers: ARWR, ALNY
Executed On: Nov 16, 2018 at 10:00 AM EST -
Discussing the Potential of Arrowhead Pharma's (ARWR) ARC-520 in Treatment of Hepatitis-B After Positive Phase 1 Results
Tickers: ARWR, BMY
Executed On: Apr 26, 2016 at 02:00 PM EDT
Free Project
Expired Projects (ARWR)
-
A Second View: Discussing Arrowhead’s Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Ticker: ARWR
Execute By: Jul 31, 2020
Upcoming & Overdue Catalysts (ARWR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ARWR)
-
Arrowhead Pharmaceuticals (ARWR) Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
Ticker: ARWR
Occurred on: Sep 16, 2019 -
Arrowhead Pharmaceuticals (ARWR) Makes Poster Presentations of New Data on ARC-AAT
Ticker: ARWR
Occurred on: Nov 14, 2016 -
FDA places clinical hold on Heparc-2004
Ticker: ARWR
Occurred on: Nov 08, 2016 -
Arrowhead Pharmaceuticals Prices $45 Million Private Offering at $5.90 per share
Ticker: ARWR
Occurred on: Aug 09, 2016 -
Arrowhead Pharma (ARWR) to Initiate Clinical Studies of ARC-521 in Hepatitis-B in 2016
Ticker: ARWR
Occurred on: Jun 10, 2016 -
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521
Ticker: ARWR
Occurred on: Jun 09, 2016 -
Arrowhead (ARWR) Has Regulatory Submissions Planned for Phase 1/2 Trial Evaluating ARC-521 in Hepatitis-B by End of Q2 2016
Ticker: ARWR
Occurred on: Apr 28, 2016 -
Arrowhead Pharma (ARWR) Presents Data on ARC-520 in Treatment of Hepatitis B at The International Liver Congress 2016
Ticker: ARWR
Occurred on: Apr 13, 2016 -
Arrowhead Pharma (ARWR) Likely to Announce New Data from Ongoing Phase 2 Studies of ARC-520 in Hepatitis-B in 2016
Ticker: ARWR
Occurred on: Apr 13, 2016
Strategic Initiatives (ARWR)
-
Novartis(NVS) to acquire The Medicines Company(MDCO) for USD 9.7 bn, adding inclisiran, investigational cholesterol-lowering therapy
Tickers: NVS, ARWR, MDCO
Announcement Date: Nov 24, 2019
